The dual role of nitric oxide in glioma

Current Pharmaceutical Design

Volumn 16, Issue 4, 2010, Pages 428-430

  Badn, Wiaam ^a   Siesjö, Peter ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chemotherapy; Gliomas; Immunotherapy; Nitric oxide; Radiotherapy

Indexed keywords

ARGININE; CARBOPLATIN; GAMMA INTERFERON; HYDROXYUREA; N (1 IMINOETHYL)LYSINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PARECOXIB; UNCLASSIFIED DRUG;

BLOOD VESSEL PERMEABILITY; BYSTANDER EFFECT; CANCER INVASION; CELL PROLIFERATION; CYTOTOXICITY; DENDRITIC CELL; GLIOMA; GLIOMA CELL; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANIMALS; CELL PROLIFERATION; GLIOMA; HUMANS; NITRIC OXIDE;

EID: 77949460820     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790232158     Document Type: Review

References (40)

1. Bakshi A, Nag TC, Wadhwa S, Mahapatra AK, Sarkar C. The expression of nitric oxide synthases in human brain tumours and peritumoral areas. J Neurol Sci 1998; 155: 196-203.
2. Broholm H, Braendstrup O, Lauritzen M. Nitric oxide synthase expression of oligodendrogliomas. Clin Neuropathol 2001; 20: 233-8.
3. Broholm H, Rubin I, Kruse A, Braendstrup O, Schmidt K, Skriver EB, et al. Nitric oxide synthase expression and enzymatic activity in human brain tumors. Clin Neuropathol 2003; 22: 273-81.
4. Erdamar S, Bagci P, Oz B, Dirican A. Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors. J BUON 2006; 11: 213-6.
5. Hara A, Okayasu I. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathol 2004; 108: 43-8.
6. Johansson AC, Hegardt P, Janelidze S, Visse E, Widegren B, Siesjö P. Enhanced expression of iNOS intratumorally and at the immunization site after immunization with IFNgamma-secreting rat glioma cells. J Neuroimmunol 2002; 123: 135-43.
7. Tanriover N, Ulu MO, Isler C, Durak H, Oz B, Uzan M, et al. Neuronal nitric oxide synthase expression in glial tumors: correlation with malignancy and tumor proliferation. Neurol Res 2008; 30: 940-4.
8. Whittle IR, Collins F, Kelly PA, Ritchie I, Ironside JW. Nitric oxide synthase is expressed in experimental malignant glioma and influences tumour blood flow. Acta Neurochirurgica 1996; 138: 870-5; discussion 875-6.
9. Zheng PP, Hop WC, Luider TM, Sillevis Smitt PA, Kros JM. Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann Neurol 2007; 62: 40-8.
10. Jeannin JF, Leon L, Cortier M, Sassi N, Paul C, Bettaieb A. Nitric oxide-induced resistance or sensitization to death in tumor cells. Nitric Oxide 2008; 19: 158-63.
11. Weyerbrock A, Baumer B, Papazoglou A. Growth inhibition and chemosensitization of exogenous nitric oxide released from NONOates in glioma cells in vitro. J Neurosurg 2009; 110: 128-36.
12. Viani P, Giussani P, Brioschi L, Bassi R, Anelli V, Tettamanti G, et al. Ceramide in nitric oxide inhibition of glioma cell growth. Evidence for the involvement of ceramide traffic. J Biol Chem 2003; 278: 9592-601.
13. Vann LR, Payne SG, Edsall LC, Twitty S, Spiegel S, Milstien S. Involvement of sphingosine kinase in TNF-alpha-stimulated tetrahydrobiopterin biosynthesis in C6 glioma cells. J Biol Chem 2002; 277: 12649-56.
14. Badn W, Visse E, Darabi A, Smith KE, Salford LG, Siesjö P. Postimmunization with IFN-gamma-secreting glioma cells combined with the inducible nitric oxide synthase inhibitor mercaptoethylguanidine prolongs survival of rats with intracerebral tumors. J Immunol 2007; 179: 4231-8.
15. Badn W, Hegardt P, Fellert MA, Darabi A, Esbjörnsson M, Smith KE, et al. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells. Scand J Immunol 2007; 65: 289-97.
16. Badn W, Kalliomäki S, Widegren B, Sjögren HO. Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma. Clin Cancer Res 2006; 12: 4714-9.
17. Siemens DR, Hu N, Sheikhi AK, Chung E, Frederiksen LJ, Pross H, et al. Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide. Cancer Res 2008; 68: 4746-53.
18. Pullen N, Fillmore H. Induction of matrix metalloproteinase-1 and glioma cell motility by nitric oxide. J Neurooncol 2009; [Epub ahead of print].
19. Lin YM, Jan HJ, Lee CC, Tao HY, Shih YL, Wei HW, et al. Dexamethasone reduced invasiveness of human malignant glioblastoma cells through a MAPK phosphatase-1 (MKP-1) dependent mechanism. Eur J Pharmacol 2008; 593: 1-9.
20. Nakano S, Matsukado K, Black KL. Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res 1996; 56: 4027-31.
21. Yin D, Wang X, Konda BM, Ong JM, Hu J, Sacapano MR, et al. Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors. Clin Cancer Res 2008; 14: 4002-9.
22. Kostourou V, Robinson SP, Whitley GSJ, Griffiths JR. Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Res 2003; 63: 4960-6.
23. Weyerbrock A, Walbridge S, Pluta RM, Saavedra JE, Keefer LK, Oldfield EH. Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas. J Neurosurg 2003; 99: 728-37.
24. Tan KH, Harrington S, Purcell WM, Hurst RD. Peroxynitrite mediates nitric oxide-induced blood-brain barrier damage. Neurochem Res 2004; 29: 579-87.
25. Kashiwagi S, Tsukada K, Xu L, Miyazaki J, Kozin SV, Tyrrell JA, et al. Perivascular nitric oxide gradients normalize tumor vasculature. Nat Med 2008; 14: 255-7.
26. Shao C, Folkard M, Michael BD, Prise KM. Targeted cytoplasmic irradiation induces bystander responses. Proc Natl Acad Sci USA 2004; 101: 13495-500.
27. Shao C, Folkard M, Michael BD, Prise KM. Bystander signaling between glioma cells and fibroblasts targeted with counted particles. Int J Cancer 2005; 116: 45-51.
28. Shao C, Folkard M, Prise KM. Role of TGF-beta1 and nitric oxide in the bystander response of irradiated glioma cells. Oncogene 2008; 27: 434-40.
29. Shao C, Prise KM, Folkard M. Signaling factors for irradiated glioma cells induced bystander responses in fibroblasts. Mutat Res 2008; 638: 139-45.
30. Yang JJ, Yin JH, Yang DI. Nitric oxide donors attenuate clongenic potential in rat C6 glioma cells treated with alkylating chemotherapeutic agents. Neurosci Lett 2007; 418: 106-10.
31. Yin JH, Yang DI, Chou H, Thompson EM, Xu J, Hsu CY. Inducible nitric oxide synthase neutralizes carbamoylating potential of 1,3-bis(2-chloroethyl)-1- nitrosourea in c6 glioma cells. J Pharmacol Exp Ther 2001; 297: 308-15.
32. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983; 158: 670-89.
33. Farias-Eisner R, Sherman MP, Aeberhard E, Chaudhuri G. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci USA 1994; 91: 9407-11.
34. Bonavida B, Baritaki S, Huerta-Yepez S, Vega MI, Chatterjee D, Yeung K. Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases. Nitric Oxide 2008; 19: 152-7.
35. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kübler H, et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 2008; 14: 8270-8.
36. Kusmartsev SA, Li Y, Chen SH. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 2000; 165: 779-85.
37. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203: 2691-702.
38. Fulda S. Apoptosis pathways and neuroblastoma therapy. Curr Pharm Des 2009; 15(4): 430-5.
39. Martin V, Liu D, Gomez-Manzano C. Encountering and advancing through antiangiogenesis therapy for gliomas. Curr Pharm Des 2009; 15(4): 353-64.
40. Sullivan R, Graham CH. Chemosensitization of cancer by nitric oxide. Curr Pharm Des 2008; 14(11): 1113-23.